Exit

Moderna loads up $604m in IPO
Investors including co-founder and Harvard professor Timothy Springer scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.
10X Genomics picks up Spatial Transcriptomics
10X Genomics has purchased genomic analysis platform Spatial Transcriptomics, based on research at Karolinska Institute and KTH Royal Institute of Technology.
Chief auditor queries WIT exit
Ireland’s Comptroller and Auditor General has highlighted issues in a Waterford Institute of Technology licensing deal that garnered low returns when the spinout in question was acquired.
Synthorx to synthesise $100m IPO
Synthorx, spun out of Scripps Research Institute, is targeting $100m in a proposed offering half a year after it raised $63m in a series C round backed by Osage University Partners.
Marinomed makes its way to stock exchange
The biopharmaceutical spinout of University of Veterinary Medicine Vienna is issuing 400,000 shares in an initial public offering that is set to fetch between $34m and $41m.
ACSL approaches flotation
Utec-backed Chiba spinout Autonomous Control Systems Laboratory has filed for an initial public offering on the Tokyo Stock Exchange and plans to list on December 21.
Exscientia scents Kinetic for acquisition
Dundee spinout Kinetic Discovery has been picked up by its peer Exscientia in a deal consolidating the equity of Frontier IP, which held stakes in both drug discovery companies.
Forescout successfully tracks SecurityMatters in $113m deal
Forescout Technologies has paid approximately $113m to acquire operational technology security provider and University of Twente spinout SecurityMatters.

Other News

News round up 12 November 2018
A round up of all the latest news on globaluniversityventuring.com for our subscribers.
Exosect put up for sale
University of Southampton spinout Exosect has been put up for sale by Hilco Streambank in an effort to salvage the pest and disease control technology producer.
Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Orchard IPO bears $200m of fruit
UCL Technology Fund-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.
Oracle catches DataFox
Stanford-StartX Fund has exited business intelligence software provider DataFox in an acquisition of undisclosed size by Oracle.
Figures show university venturing is booming
Our prediction that we would see the highest number of deals yet in a calendar year has come true with another quarter still ahead of us.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Novo pens $800m Ziylo acquisition
Ziylo, a spinout from University of Bristol that is working on a diabetes treatment, has been acquired by Novo Nordisk for a total that could exceed $800m.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
Big deal: Allied-Bristol Life Sciences
Allied Minds and Bristol-Myers Squibb are joining forces to foster biopharmaceutical research at US universities.
test reg

Login